Samsrita Labs Limited reported a net loss of ₹11.87 lakh for the quarter ended March 31, 2026, and a net loss of ₹868.60 lakh for the full fiscal year FY26. The company's board approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026.

Financial Performance

For the quarter ended March 31, 2026, the company reported total income of ₹4.96 lakh, comprising revenue from operations of ₹1.81 lakh and other income of ₹3.15 lakh. Total expenses for the quarter stood at ₹16.83 lakh. For the full year FY26, total income was ₹4.96 lakh against total expenses of ₹873.56 lakh, resulting in a net loss of ₹868.60 lakh.

Key Board Decisions

The board approved the write-off of long outstanding trade receivables and doubtful debts amounting to ₹2,08,99,089 due from M/s Mangala Savitri Bizcon Private Limited. Additionally, the board approved the write-off of long outstanding sundry creditors amounting to ₹3,14,676 as they are no longer payable. The board appointed M/s Tungala & Co., Chartered Accountants, as the internal auditors for FY 2026-27.

Financial Summary

The statutory auditors, M/s MGR & Co., issued an unmodified opinion on the audited financial results. The intimation was submitted to the exchanges in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Samsrita labs Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended 31.03.2026. The pharmaceutical company filed the certificate with stock exchanges on 07-04-2026, fulfilling its regulatory obligations under the Securities and Exchange Board of India framework.

Regulatory Compliance Filing

The compliance certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document was prepared by the company's Registrar and Transfer Agent, Venture Capital and Corporate Investments Private Limited, and submitted to both BSE Limited and Metropolitan Stock Exchange of India Limited.

Certificate Confirmation

The compliance certificate confirms that Samsrita Labs Limited has adhered to all required procedures for securities dematerialization during the quarter. According to the certificate issued by Venture Capital and Corporate Investments Private Limited, all securities received for dematerialization have been properly mutilated and cancelled after due verification.

The certificate specifically states that the names of both depositories - National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) - have been updated in the company's records as registered owners within the mandated 15-day timeframe upon receipt of valid Dematerialization Request Forms and share certificates.

Corporate Information

The filing was signed by K. Krishnam Raju, Chairman and Wholetime Director (DIN: 00874650), on behalf of Samsrita Labs Limited. The company maintains its registered and corporate office at 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad 500082.

This quarterly compliance certificate represents part of the company's ongoing regulatory obligations to maintain transparency and proper record-keeping in securities transactions and depository services.